Download MendeleyOrally-active MMP-1 sparing alpha-tetrahydropyranyl and alpha-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease
Becker, D.P., Barta, T.E., Bedell, L.J., Boehm, T.L., Bond, B.R., Carroll, J., Carron, C.P., Decrescenzo, G.A., Easton, A.M., Freskos, J.N., Funckes-Shippy, C.L., Heron, M., Hockerman, S., Howard, C.P., Kiefer, J.R., Li, M.H., Mathis, K.J., McDonald, J.J., Mehta, P.P., Munie, G.E., Sunyer, T., Swearingen, C.A., Villamil, C.I., Welsch, D., Williams, J.M., Yu, Y., Yao, J.(2010) J Med Chem 53: 6653-6680
- PubMed: 20726512
- DOI: https://doi.org/10.1021/jm100669j
- Primary Citation of Related Structures:
3KRY - PubMed Abstract:
α-Sulfone-α-piperidine and α-tetrahydropyranyl hydroxamates were explored that are potent inhibitors of MMP's-2, -9, and -13 that spare MMP-1, with oral efficacy in inhibiting tumor growth in mice and left-ventricular hypertrophy in rats and in the bovine cartilage degradation ex vivo explant system. α-Piperidine 19v (SC-78080/SD-2590) was selected for development toward the initial indication of cancer, while α-piperidine and α-tetrahydropyranyl hydroxamates 19w (SC-77964) and 9i (SC-77774), respectively, were identified as backup compounds.
Organizational Affiliation:
Pfizer Research, 700 Chesterfield Village Parkway, St. Louis, Missouri 63198, USA. dbecke3@luc.edu
